Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
- PMID: 35474266
- DOI: 10.1136/gutjnl-2022-327132
Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
Keywords: HEPATOCELLULAR CARCINOMA; IMMUNOLOGY IN HEPATOLOGY; IMMUNOTHERAPY.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23. Gut. 2023. PMID: 35197323 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical